The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Tyvense 30 mg Capsules, Hard

Takeda Pharmaceuticals International AG Ireland BranchPA23211/005/002

Main Information

Trade NameTyvense 30 mg Capsules, Hard
Active SubstancesLisdexamfetamine dimesylate
Dosage FormCapsule, hard
Licence HolderTakeda Pharmaceuticals International AG Ireland Branch
Licence NumberPA23211/005/002

Group Information



License statusAuthorised
Licence Issued08/02/2013
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in Schedule 2 of the Misuse of Drugs Regulations 2017.
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back